Fulcrum Therapeutics (FULC) Return on Capital Employed (2020 - 2025)
Historic Return on Capital Employed for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to 0.41%.
- Fulcrum Therapeutics' Return on Capital Employed fell 3000.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year decrease of 3000.0%. This contributed to the annual value of 0.09% for FY2024, which is 4000.0% up from last year.
- Latest data reveals that Fulcrum Therapeutics reported Return on Capital Employed of 0.41% as of Q3 2025, which was down 3000.0% from 0.05% recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Return on Capital Employed high stood at 0.05% for Q2 2025, and its period low was 0.59% during Q2 2021.
- Moreover, its 5-year median value for Return on Capital Employed was 0.43% (2021), whereas its average is 0.38%.
- Its Return on Capital Employed has fluctuated over the past 5 years, first soared by 3500bps in 2024, then tumbled by -3000bps in 2025.
- Fulcrum Therapeutics' Return on Capital Employed (Quarter) stood at 0.36% in 2021, then tumbled by -42bps to 0.51% in 2022, then rose by 15bps to 0.43% in 2023, then soared by 81bps to 0.08% in 2024, then crashed by -385bps to 0.41% in 2025.
- Its Return on Capital Employed stands at 0.41% for Q3 2025, versus 0.05% for Q2 2025 and 0.08% for Q4 2024.